On July 24, 2025, Zero2IPO's 2024-2025 China Industry Investment List was grandly released. This list cross-validates from three dimensions—industry, technology, and commerce—using a professional, scientific, rigorous, and quantifiable selection methodology to authentically and reliably reflect market development conditions and landscape.

Currently, the world is undergoing profound change driven jointly by industrial revolution and capital power, and the globalization of Chinese industry has entered a new narrative. As disruptive technologies such as AI large models, new energy, high-end manufacturing, and future industries explode, giving rise to numerous new industrial forms, the equity investment industry has accordingly shifted its focus to "intelligent chain integration": data as a new factor of production, computing power as new infrastructure, and capital technology implementation and scenario application, ushering in a singularity moment of boundless growth. Simultaneously, at the policy level, against the backdrop of patient capital supporting the development of new quality productive forces and the implementation of the "Six Measures for M&A" and the "Eight Measures for the STAR Market," China's capital market equity investment has entered a new stage.

In this selection, Efung Capital, its outstanding investment performance and industry influence, was honored as a [2024-2025 Best Investment Institution in China's Healthcare Sector].

Looking ahead, Efung Capital will unswervingly anchor itself in the biopharmaceutical track, leveraging capital empowerment, industrial collaboration, and long-term companionship to drive the transformation of technological innovation achievements and accelerate the high-quality development of the biopharmaceutical industry.